Marpai, Inc. MRAI
We take great care to ensure that the data presented and summarized in this overview for Marpai, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MRAI
Top Purchases
Top Sells
About MRAI
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. It also develops artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent events related to diagnostic errors, hospital visits, and administrative issues. The company was incorporated in 2021 and is headquartered in New York, New York.
Insider Transactions at MRAI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 28
2024
|
Damien Lamendola Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
1,351,351
+21.56%
|
$0
$0.48 P/Share
|
|
Jun 03
2024
|
Yaron Eitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+1.03%
|
$0
$0.61 P/Share
|
|
May 29
2024
|
Mohsen Moazami |
SELL
Open market or private sale
|
Direct |
15,000
-30.0%
|
$0
$0.68 P/Share
|
|
May 29
2024
|
Steve Andrew Johnson Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+0.94%
|
$0
$0.65 P/Share
|
|
May 28
2024
|
Robert M Pons |
BUY
Open market or private purchase
|
Direct |
5,000
+5.61%
|
$0
$0.87 P/Share
|
|
May 24
2024
|
Steve Andrew Johnson Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.35%
|
$5,000
$1.2 P/Share
|
|
May 23
2024
|
Sagiv Shiv |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
May 23
2024
|
Damien Lamendola Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
600,000
+14.77%
|
-
|
|
May 23
2024
|
Steve Andrew Johnson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+49.33%
|
-
|
|
May 23
2024
|
Yaron Eitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+8.26%
|
-
|
|
May 23
2024
|
Colleen Di Claudio |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
May 23
2024
|
Mohsen Moazami |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
May 16
2024
|
Robert M Pons |
BUY
Open market or private purchase
|
Direct |
5,000
+5.94%
|
$10,000
$2.1 P/Share
|
|
May 10
2024
|
Damien Lamendola Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+4.55%
|
$20,000
$2.49 P/Share
|
|
May 10
2024
|
Steve Andrew Johnson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+34.34%
|
$10,000
$2.6 P/Share
|
|
May 10
2024
|
Yaron Eitan Director |
BUY
Open market or private purchase
|
Direct |
5,000
+0.82%
|
$10,000
$2.66 P/Share
|
|
May 10
2024
|
Michael Charles Dendy |
SELL
Open market or private sale
|
Direct |
42,752
-41.17%
|
$85,504
$2.32 P/Share
|
|
May 10
2024
|
Michael Charles Dendy |
SELL
Open market or private sale
|
Indirect |
2,371
-11.86%
|
$4,742
$2.4 P/Share
|
|
Mar 07
2024
|
Damien Lamendola Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
910,000
+24.13%
|
$910,000
$1.65 P/Share
|
|
Jan 17
2024
|
Michael Charles Dendy |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+32.5%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.49M shares |
|---|---|
| Open market or private purchase | 3.83M shares |
| Open market or private sale | 60.1K shares |
|---|